Karyopharm Therapeutics Inc. (KPTI) Reaches $17.50 After 8.00% Down Move; Willis Lease Finance (WLFC)’s Sentiment Is 0.86

June 4, 2018 - By Kurt Siggers

The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is a huge mover today! The stock decreased 3.42% or $0.62 during the last trading session, reaching $17.5. About 587,214 shares traded. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 94.50% since June 4, 2017 and is uptrending. It has outperformed by 81.93% the S&P500.The move comes after 9 months negative chart setup for the $1.05 billion company. It was reported on Jun, 4 by Barchart.com. We have $16.10 PT which if reached, will make NASDAQ:KPTI worth $84.24M less.

Willis Lease Finance Corp (WLFC) investors sentiment decreased to 0.86 in 2018 Q1. It’s down -0.43, from 1.29 in 2017Q4. The ratio worsened, as 19 investment professionals increased or started new stock positions, while 22 reduced and sold stock positions in Willis Lease Finance Corp. The investment professionals in our database now possess: 2.21 million shares, down from 2.23 million shares in 2017Q4. Also, the number of investment professionals holding Willis Lease Finance Corp in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 5 Reduced: 17 Increased: 12 New Position: 7.




Another recent and important Willis Lease Finance Corporation (NASDAQ:WLFC) news was published by Nasdaq.com which published an article titled: “Willis Lease Finance Corporation Reports First Quarter Pretax Profit of $9.6 Million” on May 07, 2018.

Since January 1, 0001, it had 1 insider purchase, and 11 sales for $564,598 activity.

The stock decreased 1.95% or $0.6362 during the last trading session, reaching $31.9638. About 12,105 shares traded. Willis Lease Finance Corporation (WLFC) has risen 24.40% since June 4, 2017 and is uptrending. It has outperformed by 11.83% the S&P500.

Willis Lease Finance Corporation, together with its subsidiaries, leases commercial aircraft engines and other aircraft-related equipment to air carriers, manufacturers, and overhaul/repair facilities worldwide. The company has market cap of $203.25 million. It operates through two divisions, Equipment Leasing and Spare Parts Sales. It has a 3.3 P/E ratio. The firm also purchases and resells new and used commercial aircraft engines, as well as sells aircraft engine parts and materials.

Menta Capital Llc holds 0.12% of its portfolio in Willis Lease Finance Corporation for 15,956 shares. Rbf Capital Llc owns 30,000 shares or 0.12% of their US portfolio. Moreover, Eam Investors Llc has 0.11% invested in the company for 19,999 shares. The New York-based Maltese Capital Management Llc has invested 0.06% in the stock. Bridgeway Capital Management Inc, a Texas-based fund reported 143,550 shares.

More important recent Karyopharm Therapeutics Inc. (NASDAQ:KPTI) news were published by: Nasdaq.com which released: “Karyopharm to Present Selinexor Phase 2/3 SEAL Data at the American Society of Clinical Oncology 2018 Annual …” on June 01, 2018, also Globenewswire.com published article titled: “Report: Exploring Fundamental Drivers Behind PDC Energy, Black Stone Minerals, BJ’s Restaurants, Karyopharm …”, Seekingalpha.com published: “Karyopharm Therapeutics’ (KPTI) CEO Michael Kauffman on Q1 2018 Results – Earnings Call Transcript” on May 10, 2018. More interesting news about Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was released by: Seekingalpha.com and their article: “Week In Review: Grail, An Oncology Diagnostics Company, Taps China Investors For $300 Million” with publication date: May 27, 2018.

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 11 have Buy rating, 1 Sell and 1 Hold. Therefore 85% are positive. Karyopharm Therapeutics Inc. had 39 analyst reports since August 11, 2015 according to SRatingsIntel. Canaccord Genuity maintained Karyopharm Therapeutics Inc. (NASDAQ:KPTI) rating on Tuesday, May 15. Canaccord Genuity has “Buy” rating and $2400 target. The firm earned “Outperform” rating on Tuesday, June 28 by Robert W. Baird. Cantor Fitzgerald maintained it with “Buy” rating and $1800 target in Monday, April 30 report. The firm has “Buy” rating by Robert W. Baird given on Thursday, March 15. The rating was initiated by Raymond James with “Outperform” on Friday, May 27. Canaccord Genuity maintained the stock with “Buy” rating in Tuesday, August 8 report. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) earned “Buy” rating by H.C. Wainwright on Thursday, January 11. RBC Capital Markets maintained it with “Buy” rating and $22.0 target in Friday, March 2 report. Jefferies maintained Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Wednesday, April 25 with “Buy” rating. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) earned “Hold” rating by Jefferies on Wednesday, January 6.

Since December 11, 2017, it had 0 insider buys, and 31 sales for $3.58 million activity. On Monday, May 7 the insider Shacham Sharon sold $167,747. Shares for $124,829 were sold by Kauffman Michael on Monday, April 9. 2,500 shares were sold by Primiano Christopher Brett, worth $37,527 on Thursday, February 15. Mirza Mansoor Raza also sold $40,000 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Monday, March 5.

Analysts await Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report earnings on August, 14. They expect $-0.76 earnings per share, down 18.75% or $0.12 from last year’s $-0.64 per share. After $-0.78 actual earnings per share reported by Karyopharm Therapeutics Inc. for the previous quarter, Wall Street now forecasts -2.56% EPS growth.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.